🇺🇸 CABOZANTINIB S-MALATE in United States

83 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 13 reports (15.66%)
  2. Malignant Neoplasm Progression — 11 reports (13.25%)
  3. Decreased Appetite — 10 reports (12.05%)
  4. Death — 8 reports (9.64%)
  5. Hypertension — 8 reports (9.64%)
  6. Fatigue — 7 reports (8.43%)
  7. Malaise — 7 reports (8.43%)
  8. Stomatitis — 7 reports (8.43%)
  9. Asthenia — 6 reports (7.23%)
  10. Nausea — 6 reports (7.23%)

Source database →

CABOZANTINIB S-MALATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is CABOZANTINIB S-MALATE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for CABOZANTINIB S-MALATE in United States?

Marketing authorisation holder not available in our data.